Utilisation and expenditures in the treatment of patients with gastro-oesophageal reflux disease

Disease Management and Health Outcomes

Volumn 4, Issue 6, 1998, Pages 325-336

  Prevalence, ^a   Factors, High Cost ^b   Lair, Tamra J ^b   Fu, Qinggong ^b   Anderson, Daniel R ^b   Crawley, Joseph A ^b  

^a Watson Wyatt Worldwide   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; FAMOTIDINE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; RANITIDINE; SUCRALFATE;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG UTILIZATION; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; LABORATORY TEST; MANAGED CARE ORGANIZATION; PREVALENCE; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0032426259     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199804060-00003     Document Type: Article

References (3)

1. Spechler SJ. Epidemiology and natural history of gastro-esophageal reflux disease. Digestion 1992; 51 Suppl. 1: 24-9
2. Katz PO. Pathogenesis and management of gastroesophageal reflux disease. J Clin Gasteroenterol 1991; 13 Suppl. 2: S6-S15
3. Mold JW, Reed LE, Davis AB, et al. Prevalence of gastroesophageal reflux in elderly patients in a primary care setting. Am J Gastroenterol 1991; 86: 965-70